89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-29
Target enrollment:
Participant gender:
Summary
A prospective, open-label, phase 2 study to explore CAIX expression through
89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients
with solid tumors.